Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Targeting of folate receptor   on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells

(2015) R. C. Lynn et al.   BLOOD

Immunotherapy in acute myeloid leukemia

(2015) Dolores A. Grosso et al.   CANCER

Cancer gene therapy with T cell receptors and chimeric antigen receptors

(2015) Hans J Stauss et al.   CURRENT OPINION IN PHARMACOLOGY

Bispecific antibodies

(2015) Roland E. Kontermann et al.   DRUG DISCOVERY TODAY

Programmed death-1 checkpoint blockade in acute myeloid leukemia

(2015) Alison Sehgal et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia

(2015) Radoslav Mladenov et al.   INTERNATIONAL JOURNAL OF CANCER

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge

(2015) Carlos Rodriguez-Galindo et al.   JOURNAL OF CLINICAL ONCOLOGY

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

(2015) Thomas Köhnke et al.   Journal of Hematology & Oncology

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

(2015) David M. Barrett et al.   JOURNAL OF IMMUNOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

(2015) S S Kenderian et al.   LEUKEMIA

Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia

(2015) Michael Durben et al.   MOLECULAR THERAPY

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

(2015) Quan-shun Wang et al.   MOLECULAR THERAPY

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

(2015) Tao Dao et al.   NATURE BIOTECHNOLOGY

Novel immunotherapies in lymphoid malignancies

(2015) Connie Lee Batlevi et al.   Nature Reviews Clinical Oncology

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advances in Anticancer Immunotoxin Therapy

(2015) C. Alewine et al.   ONCOLOGIST

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

(2015) Kimberly H. Harrington et al.   PLoS One

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia

(2015) Helena Ågerstam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts

(2015) R Aliperta et al.   Blood Cancer Journal

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

(2015) S Y Kim et al.   Blood Cancer Journal

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330

(2015) G S Laszlo et al.   Blood Cancer Journal

Update on Antigen-Specific Immunotherapy of Acute Myeloid Leukemia

(2015) Sarah A. Buckley et al.   Current Hematologic Malignancy Reports

Targeting Human C-Type Lectin-like Molecule-1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

(2014) Hua Lu et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Immunotoxins for leukemia

(2014) A. S. Wayne et al.   BLOOD

Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells

(2014) G. Romain et al.   BLOOD

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

(2014) A. E. Frankel et al.   BLOOD

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

The past and future of CD33 as therapeutic target in acute myeloid leukemia

(2014) George S. Laszlo et al.   BLOOD REVIEWS

Immune modulation for cancer therapy

(2014) J Naidoo et al.   BRITISH JOURNAL OF CANCER

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

(2014) C. O'Hear et al.   HAEMATOLOGICA

Targetedex vivoreduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins

(2014) Sonja Schiffer et al.   INTERNATIONAL JOURNAL OF CANCER

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

(2014) Alan S. Gamis et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

(2014) Robert K Hills et al.   LANCET ONCOLOGY

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

(2014) S J Busfield et al.   LEUKEMIA

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

(2014) I Pizzitola et al.   LEUKEMIA

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

(2014) Simon Z. He et al.   LEUKEMIA & LYMPHOMA

Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia

(2014) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

The development of immunoconjugates for targeted cancer therapy

(2014) Brandon G. Smaglo et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

(2013) A. Mardiros et al.   BLOOD

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)

(2013) J. Greiner et al.   BLOOD

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

Immunotherapeutic strategies for relapse control in acute myeloid leukemia

(2013) Anna Martner et al.   BLOOD REVIEWS

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor

(2013) Sarah Tettamanti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin

(2013) Roland Walter   Frontiers in Bioscience-Landmark

Radioimmunotherapy for hematopoietic cell transplantation

(2013) Joseph G Jurcic   Immunotherapy

Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia

(2013) Akihiro Takeshita   INTERNATIONAL JOURNAL OF HEMATOLOGY

Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

(2013) C Arndt et al.   LEUKEMIA

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody

(2013) T. Dao et al.   Science Translational Medicine

Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia

(2013) Amnon Peled et al.   Theranostics

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

(2012) G. J. Ossenkoppele et al.   BLOOD

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

(2012) N. Vey et al.   BLOOD

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

(2012) R. B. Walter et al.   BLOOD

Antibody-Based Immunotherapy of Cancer

(2012) Louis M. Weiner et al.   CELL

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies

(2012) M. R. Kuhne et al.   CLINICAL CANCER RESEARCH

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

(2012) G. Borthakur et al.   HAEMATOLOGICA

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

(2012) M. A. Sekeres et al.   HAEMATOLOGICA

Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts

(2012) Alexandre P.A. Theocharides et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

(2012) S Anguille et al.   LEUKEMIA

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

(2011) J. M. Pagel et al.   BLOOD

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

(2011) Simona Lapusan et al.   INVESTIGATIONAL NEW DRUGS

Vaccines as consolidation therapy for myeloid leukemia

(2011) Gheath Alatrash et al.   Expert Review of Hematology

Pretargeted Radioimmunotherapy for Hematologic and Other Malignancies

(2010) Roland B. Walter et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

(2010) Yoshikane Kikushige et al.   Cell Stem Cell

Sequential Cytarabine and  -Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

(2010) T. L. Rosenblat et al.   CLINICAL CANCER RESEARCH

Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors

(2010) V. Marin et al.   HAEMATOLOGICA

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

(2010) R Majeti   ONCOGENE

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

(2010) V. F. Van Tendeloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Peptide vaccines for patients with acute myeloid leukemia

(2009) Michael Schmitt et al.   Expert Review of Vaccines

Monoclonal antibodies against IREM-1: potential for targeted therapy of AML

(2009) W Korver et al.   LEUKEMIA

Targeting FLT3 for the Treatment of Leukemia

(2008) Donald Small   SEMINARS IN HEMATOLOGY